Covalent bond

Covalent Media Systems, LLC and Launch Cart, Inc. Announce Strategic Joint Marketing Agreement

Retrieved on:

Tuesday, March 5, 2024

AI, Advertising, Business, Covalent bond, E-commerce, Agreement, Partnership, Online shopping

ESCONDIDO, CA, March 05, 2024 (GLOBE NEWSWIRE) -- Covalent Media Systems, LLC ("Covalent"), a leading proprietary AI ecosystem platform, and Launch Cart, Inc. ("Launch Cart"), a top innovator in eCommerce and digital marketing solutions, are thrilled to announce a Joint Marketing Agreement effective as of February 20, 2024.

Key Points:

ESCONDIDO, CA, March 05, 2024 (GLOBE NEWSWIRE) -- Covalent Media Systems, LLC ("Covalent"), a leading proprietary AI ecosystem platform, and Launch Cart, Inc. ("Launch Cart"), a top innovator in eCommerce and digital marketing solutions, are thrilled to announce a Joint Marketing Agreement effective as of February 20, 2024.
This venture will leverage both companies' strengths to provide forward-thinking solutions in the global media, data, advertising, and entertainment markets.
Under this agreement, Covalent and Launch Cart will coordinate joint sales and marketing activities to offer their respective customer bases more comprehensive services.
Greg Writer, CEO of Launch Cart, Inc., commented, "Collaborating with Covalent Media Systems is an exciting opportunity for Launch Cart.

LG Energy Solution Strengthens Partnership with WesCEF, Secures Stable Lithium Supply Chain for the North American Market

Retrieved on:

Tuesday, February 13, 2024

Lithium, LG Energy Solution, KRX, Senior, Calendar, Sociedad, Morazán, Covalent bond, Energy, SQM, Partnership

LG Energy Solution signs a second offtake agreement with WesCEF, expands its supply chain for competitive lithium procurement

Key Points:

LG Energy Solution signs a second offtake agreement with WesCEF, expands its supply chain for competitive lithium procurement
Lithium hydroxide and lithium concentrate from WesCEF's Mt.
Under the agreement, WesCEF will supply LG Energy Solution up to 85,000 tons of lithium concentrate, which could be utilized in producing around 11,000 tons of lithium hydroxide, a crucial raw material for cathodes.
As part of its efforts to further enhance its lithium supply chain, LG Energy Solution has also secured a partnership with SQM, a global mining company based in Chile and also an investor in the Mt.
Holland lithium project, as two companies signed a new long-term supply agreement for lithium carbonate and lithium hydroxide last year.

AP3 and Wafra Form New Investment Platform to Pursue Private Equity Co-investments

Retrieved on:

Tuesday, December 5, 2023

Networks, Finance, Professional Services, Technology, Asset Management, Constellation, Like a Boss (film), Investment, Private equity, Multimedia, AP3, Security (finance), Cryptocurrency, Financial services, Wafra, Covalent bond

The Third Swedish National Pension Fund (“AP3”) and Wafra Inc. (“Wafra”) today announced the formation of an investment platform called Covalent.

Key Points:

The Third Swedish National Pension Fund (“AP3”) and Wafra Inc. (“Wafra”) today announced the formation of an investment platform called Covalent.
The platform is focused on pursuing a new approach to private equity co-investing, harnessing the capabilities, networks and experience of a small number of large, forward-thinking, global asset owners.
View the full release here: https://www.businesswire.com/news/home/20231205448158/en/
Covalent’s founding members believe that the prevailing approaches to private equity co-investment are ripe for positive transformation.
Commenting on the launch of Covalent, Henrik Nordlander, Head of Private Equity at AP3 said, “For AP3 this is a way to accomplish cost efficient, sustainable asset management as we strive to be a world class investor.

Fantom Sonic, Gas Monetization Program Headline An Innovation-Focused 2023 for Fantom Foundation

Retrieved on:

Tuesday, December 12, 2023

GEORGE TOWN, Cayman Islands, Dec. 12, 2023 /PRNewswire/ -- The Fantom Foundation ("the Foundation"), the team supporting the development of the Fantom blockchain, recaps its 2023 campaign for both the Foundation and the Fantom blockchain. The launch of Fantom Sonic into its testnet environment headlines the Foundation's activity over the past year, as the company's new technology stack is anticipated to achieve over 2,000 transactions per second (TPS) at a one second average finality. The upgrade highlights the Foundation's commitment to innovating the underlying platform of the Fantom blockchain.

Key Points:

In addition to multiple upgrades to the Fantom network and ecosystem, the Foundation worked alongside the likes of AWS, Google, LayerZero, Axelar, and others to further enhance the Fantom experience
GEORGE TOWN, Cayman Islands, Dec. 12, 2023 /PRNewswire/ -- The Fantom Foundation ("the Foundation"), the team supporting the development of the Fantom blockchain, recaps its 2023 campaign for both the Foundation and the Fantom blockchain.
In addition to Sonic, the Foundation implemented multiple strategic integrations, upgrades, and partnerships on behalf of Fantom, including its gas monetization program, ecosystem vault, improved bridging capabilities, and global expansion.
The Gas Monetization program on Fantom provides visionary dApps with a sustainable income by offering them a 15% share of the gas fees they generate, similar to a web2 ad-revenue model that sees platforms reward creators that drive their success.
Fantom Foundation CEO, Michael Kong, added: "Our team is constantly looking to support and grow the Fantom network in any capacity that we can.

Uniblock Raises a $2.3M Funding Round

Retrieved on:

Wednesday, November 15, 2023

Toronto Metropolitan University, Blockchain, SF, Product management, NFT, Intelligence, TMU, Ivey Business School, University, AQN, API, Alchemy, Business, Coinbase, Cryptocurrency, Covalent bond, Cadenza

SAN FRANCISCO, Nov. 15, 2023 /PRNewswire/ -- Uniblock, a San Francisco and Toronto-based startup that's transforming how developers build on the blockchain through its pioneering Unified Web3 API platform, is thrilled to announce a funding round of $2.3 million. The round includes participation from Cadenza, Blockchain Founders Fund, Side Door Ventures, AQN, Serafund, Outsider Ventures, and others.

Key Points:

The round includes participation from Cadenza, Blockchain Founders Fund, Side Door Ventures, AQN, Serafund, Outsider Ventures, and others.
Uniblock's goal is to be the default developer platform that companies use when building for the blockchain.
Uniblock aims to unify this scattered market by connecting the best blockchain tools such as Alchemy, thirdweb, Moralis, Parsiq, Covalent, QuickNode and many more, into one easy-to-use platform.
Uniblock envisions a future where every company can easily build for the blockchain and maintain their product using a singular platform.

Lilly Announces Details of Pirtobrutinib Presentations in B-Cell Malignancies at 2023 ASH Annual Meeting

Retrieved on:

Thursday, November 2, 2023

INDIANAPOLIS, Nov. 2, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of pirtobrutinib, a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, will be presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 9-12 in San Diego.

Key Points:

INDIANAPOLIS, Nov. 2, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of pirtobrutinib, a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, will be presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 9-12 in San Diego.
The presentations will provide updated, longer follow-up clinical safety and efficacy data for approved and investigational uses of pirtobrutinib from the ongoing Phase 1/2 BRUIN study in multiple B-cell malignancies.
In mantle cell lymphoma (MCL), an oral presentation will provide updated safety and efficacy results of pirtobrutinib in all patients, including those with biologically high-risk relapsed or refractory MCL.
Additionally, poster presentations will provide data on the clinical impact of pirtobrutinib following cBTKi treatment across other B-cell malignancies.

New Covalent Platform Sets Industry High Standard for Forward Carbon Removal Credits

Retrieved on:

Tuesday, October 3, 2023

Carbon, Covalent bond, Climate, DAC, Certification, CDR, Climate change, SAN, Goa Carbon Limited, CO2, Cryptocurrency, Seaweed

SAN FRANCISCO, Oct. 3, 2023 /PRNewswire/ -- Climate technology startup Covalent announced today the first forward-crediting platform for carbon removal (CDR) projects that ensure at least 1,000 years of permanence, connecting innovators with new financing. The independent validation of forward credits accelerates early-stage CDR projects working to quickly scale climate change solutions. The announcement, made at Carbon Unbound Europe, launches a new era of trust for the carbon removal industry.

Key Points:

The independent validation of forward credits accelerates early-stage CDR projects working to quickly scale climate change solutions.
The announcement, made at Carbon Unbound Europe, launches a new era of trust for the carbon removal industry.
"By connecting CDR projects with project financing, Covalent accelerates the scaling of the carbon removal industry."
Following the launch, nearly 1 million forward carbon removal credits were issued on the platform by Carbon Limit, a Florida-based firm that creates CaptureCrete, a cement additive enabling concrete to actively absorb carbon dioxide (CO2).

BridGene Biosciences to Present at Hippo Pathway Targeted Drug Development Summit

Retrieved on:

Thursday, May 18, 2023

KRAS, Covalent bond, Andrew Bridgen, Therapy, Exception, Cancer, Regenerative medicine, TEAD, Fibrosis, SAN, Drug development, Biology, Hippopotamus, Pharmaceutical industry

SAN JOSE, Calif., May 18, 2023 /PRNewswire/ -- BridGene Biosciences, Inc. , a biotechnology company using a proprietary chemoproteomics technology to discover and develop small molecules for high-value, traditionally undruggable targets, announced that Wolf Wiedemeyer, Ph.D., head of biology at BridGene, will be giving a presentation, titled "A Covalent TEAD Inhibitor with Exceptional Anti-cancer Activity & Combination Potential," at the 2nd Annual Hippo Pathway Targeted Drug Development Summit on May 24 in Boston.

Key Points:

SAN JOSE, Calif., May 18, 2023 /PRNewswire/ -- BridGene Biosciences, Inc. , a biotechnology company using a proprietary chemoproteomics technology to discover and develop small molecules for high-value, traditionally undruggable targets, announced that Wolf Wiedemeyer, Ph.D., head of biology at BridGene, will be giving a presentation, titled "A Covalent TEAD Inhibitor with Exceptional Anti-cancer Activity & Combination Potential," at the 2nd Annual Hippo Pathway Targeted Drug Development Summit on May 24 in Boston.
The 2nd Annual Hippo Pathway Targeted Drug Development Summit is an industry-led forum, aimed at accelerating the understanding and opportunity of the Hippo signaling pathway in progressing the discovery, translation, and clinical development of safe and effective therapeutics within oncology, regenerative medicine, fibrosis, and beyond.
"Our IMTAC™ live-cell chemoproteomic platform to identify small molecules against challenging targets has successfully identified several potent and drug-like covalent ligands for TEAD and provided the foundation for BridGene to discover its pre-clinical oncology drug candidate BGI-9004," said CEO and Co-founder Ping Cao, Ph.D.
Details regarding the poster presentation are as follows:

Loxo@Lilly Announces Details of Presentations at 2023 European Hematology Association (EHA) Annual Meeting

Retrieved on:

Thursday, May 11, 2023

CLL, Covalent bond, Interim, Chronic lymphocytic leukemia, Lymphoid leukemia, Mantle cell lymphoma, Malignancy, PRO, BTK, LLY, Patient, Annual general meeting, EHA, Oral, Eli Lilly and Company, MCL, NYSE, Pharmaceutical industry

INDIANAPOLIS, May 11, 2023 /PRNewswire/ -- Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), today announced that data from its oncology portfolio will be presented at the 2023 European Hematology Association (EHA) Annual Meeting, to be held June 8 – 11, 2023, in Frankfurt, Germany, and virtually.

Key Points:

INDIANAPOLIS, May 11, 2023 /PRNewswire/ -- Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), today announced that data from its oncology portfolio will be presented at the 2023 European Hematology Association (EHA) Annual Meeting, to be held June 8 – 11, 2023, in Frankfurt, Germany, and virtually.
The company-sponsored abstracts include new analyses of clinical data in approved and investigational uses based on the BRUIN Phase 1/2 trial evaluating Jaypirca™ (pirtobrutinib) in patients with B-cell malignancies previously treated with a covalent Bruton's tyrosine kinase (BTK) inhibitor, including mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL).
A list of presentations, along with their viewing details, are shared below.
Genomic Evolution and Resistance to Pirtobrutinib in Covalent BTK-Inhibitor (cBTKi) Pre-treated Chronic Lymphocytic Leukemia (CLL) Patients: Results from the Phase 1/2 BRUIN Study
Patient-Reported Outcomes (PRO) Among Patients with Mantle Cell Lymphoma Receiving Pirtobrutinib After Prior Covalent BTKi: Interim PRO Analysis from the BRUIN Phase 1/2 Study
A First-in-Human Phase 1 Study of Oral LOXO-338, a Selective BCL2 Inhibitor, in Patients with Advanced Hematologic Malignancies

Horizen Integrates Covalent for EON, the New Public EVM-Compatible Sidechain on Horizen, to Bring Data Visibility and Unified Data Points to Developers

Retrieved on:

Wednesday, April 26, 2023

Technology, Web3, Blockchain, Security, EON, Ethereum, Dapp, API, Covalent bond, Entrepreneurship, Partnership, Unified, EVM, Gobi Desert, Cryptocurrency, Horizon

This partnership will bring about massive data accessibility and transparency to Horizen’s new EVM-compatible smart contracting platform, EON, and provide its developers billions of data points and comprehensive insights into on-chain data.

Key Points:

This partnership will bring about massive data accessibility and transparency to Horizen’s new EVM-compatible smart contracting platform, EON, and provide its developers billions of data points and comprehensive insights into on-chain data.
The integration with Covalent will allow developers to leverage an increasingly accelerated volume of blockchain data points to efficiently build and deploy decentralized applications (dApps) on Horizen EON.
As a result of the integration, Horizen's Gobi public testnet data is now available on-chain in the API, powered by Covalent.
Covalent's Unified API brings forth visibility to billions of web3 data points, offering the most robust blockchain data API and infrastructure for the entire blockchain ecosystem.